Tesaro Inc. (NASDAQ:TSRO) hit a new 52-week high during trading on Thursday . The company traded as high as $94.01 and last traded at $92.81, with a volume of 340,280 shares traded. The stock had previously closed at $92.33.

A number of equities research analysts have recently commented on the stock. Robert W. Baird assumed coverage on shares of Tesaro in a research note on Monday, July 18th. They set an “outperform” rating and a $105.00 price objective on the stock. Wells Fargo & Co. reissued an “outperform” rating on shares of Tesaro in a research note on Thursday, June 30th. Wedbush reissued a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Mizuho reissued an “outperform” rating and issued a $67.00 price target on shares of Tesaro in a research note on Thursday, June 30th. Finally, FBR & Co reissued a “buy” rating on shares of Tesaro in a research note on Thursday, June 30th. Two investment analysts have rated the stock with a hold rating, ten have assigned a buy rating and one has given a strong buy rating to the company’s stock. Tesaro has a consensus rating of “Buy” and an average target price of $76.50.

The stock’s market cap is $4.22 billion. The firm’s 50-day moving average price is $64.24 and its 200 day moving average price is $47.33.

Tesaro (NASDAQ:TSRO) last issued its earnings results on Thursday, May 5th. The biopharmaceutical company reported ($2.22) earnings per share (EPS) for the quarter, missing the consensus estimate of ($1.69) by $0.53. The business had revenue of $0.31 million for the quarter, compared to analyst estimates of $2.48 million. During the same period in the previous year, the business earned ($1.30) earnings per share. Equities research analysts forecast that Tesaro Inc. will post ($7.16) earnings per share for the current fiscal year.

In other news, VP Edward C. English sold 7,000 shares of Tesaro stock in a transaction that occurred on Friday, June 10th. The shares were sold at an average price of $40.75, for a total value of $285,250.00. Following the completion of the sale, the vice president now directly owns 3,500 shares in the company, valued at $142,625. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, VP Jeffrey H. Hanke sold 12,500 shares of Tesaro stock in a transaction that occurred on Thursday, June 30th. The stock was sold at an average price of $74.35, for a total transaction of $929,375.00. Following the completion of the sale, the vice president now owns 12,500 shares of the company’s stock, valued at $929,375. The disclosure for this sale can be found here.

Several hedge funds recently made changes to their positions in TSRO. Nationwide Fund Advisors raised its stake in shares of Tesaro by 1.3% in the fourth quarter. Nationwide Fund Advisors now owns 26,647 shares of the biopharmaceutical company’s stock worth $1,394,000 after buying an additional 330 shares in the last quarter. California State Teachers Retirement System raised its stake in shares of Tesaro by 1.8% in the fourth quarter. California State Teachers Retirement System now owns 43,152 shares of the biopharmaceutical company’s stock worth $2,258,000 after buying an additional 752 shares in the last quarter. Rhumbline Advisers raised its stake in shares of Tesaro by 9.3% in the fourth quarter. Rhumbline Advisers now owns 22,403 shares of the biopharmaceutical company’s stock worth $1,172,000 after buying an additional 1,915 shares in the last quarter. TD Asset Management Inc. raised its stake in shares of Tesaro by 4.5% in the fourth quarter. TD Asset Management Inc. now owns 91,006 shares of the biopharmaceutical company’s stock worth $4,761,000 after buying an additional 3,900 shares in the last quarter. Finally, ProShare Advisors LLC bought a new stake in shares of Tesaro during the fourth quarter worth approximately $1,864,000.

TESARO, Inc (TESARO) is oncology-focused biopharmaceutical company. The Company acquires, in-licenses and develops oncology product candidates. The Company has in-licensed and are developing three clinical-stage product candidates, rolapitant, niraparib and TSR-011. Rolapitant is a potent and long-acting neurokinin-1, or NK-1, receptor antagonist for the prevention of chemotherapy induced nausea and vomiting (CINV); Niraparib, formerly known as MK-4827, is an orally active and potent poly (ADP-ribose) polymerase, and TSR-011 is an orally available targeted anti-cancer agent which is a potent inhibitor of both anaplastic lymphoma kinase (ALK) and tropomyosin-related kinase (TRK).

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.